Cargando…
Sonidegib, a novel smoothened inhibitor for the treatment of advanced basal cell carcinoma
Basal cell carcinoma (BCC) is the most common nonmelanoma skin cancer. If left untreated, BCCs can become locally aggressive or even metastasize. Currently available treatments include local destruction, surgery, and radiation. Systemic options for advanced disease are limited. The Hedgehog (Hh) pat...
Autores principales: | Doan, Hung Q, Silapunt, Sirunya, Migden, Michael R |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5028081/ https://www.ncbi.nlm.nih.gov/pubmed/27695345 http://dx.doi.org/10.2147/OTT.S108171 |
Ejemplares similares
-
Switching Hedgehog inhibitors and other strategies to address resistance when treating advanced basal cell carcinoma
por: Doan, Hung Q., et al.
Publicado: (2021) -
Advances in Management and Therapeutics of Cutaneous Basal Cell Carcinoma
por: Chen, Olivia M., et al.
Publicado: (2022) -
Sonidegib for the Treatment of Advanced Basal Cell Carcinoma
por: Brancaccio, Gabriella, et al.
Publicado: (2020) -
Treatment of Leg Veins for Restless Leg Syndrome: A Retrospective Review
por: Sundaresan, Swaminathan, et al.
Publicado: (2019) -
Effects of Sonidegib Following Dose Reduction and Treatment Interruption in Patients with Advanced Basal Cell Carcinoma During 42-Month BOLT Trial
por: Lewis, Karl, et al.
Publicado: (2021)